{
  "_id": "7a013cfff88efb7992191bb40ab22c76f1f8f230ea0fe8b74036eaf0c16c12a3",
  "feed": "wall-street-journal",
  "title": "VC Daily: Omicron is Latest Test of Biotech Startups' Resilience",
  "text": "<p>But he added that Omicron is a challenge the industry will have to confront. On Wednesday, JPMorgan said the annual J.P. Morgan Healthcare Conference in January, normally held in San Francisco, would be virtual.</p><p>\"We appreciate your understanding and look forward to seeing you back in San Francisco in-person in 2023,\" the firm said in an email to conference attendees.</p><p>Otello Stampacchia, founder and managing director of Omega Funds, a life-sciences venture firm, said he has been advising portfolio companies to stop in-person board meetings and board dinners.</p><p>\"There is a natural tendency to want to go back to normal,\" Dr. Stampacchia said. \"But we have to face reality.\"</p><p>And now on to the news...</p><p>Top News</p><p>Biotech bets on AI, genetics. Biotechnology company Verge Genomics has raised $98 million in new venture capital to use artificial intelligence and human genetics to uncover treatments for neurological diseases.</p><p>The complexity of diseases such as Parkinson's and amyotrophic lateral sclerosis has thwarted many attempts to develop better treatments for neurological illnesses. Conventionally, companies have relied on a relatively small number of drug targets when studying potential treatments.</p><p>Verge and some other biotechs are betting AI and large-scale genetics will improve success rates by increasing the number of brain-disease targets and helping researchers optimize drug compounds.</p><p>Verge genetically profiles brains and spinal cords from patients who have had diseases such as Alzheimer's and Parkinson's and uses machine learning to map out causes of the disease. Verge's lead drug is a potential treatment for ALS, a progressive condition that affects nerve cells controlling voluntary muscle movement.</p><p>$11.7 Billion</p><p>The amount that biotech company CSL Ltd. agreed to pay to acquire speciality-pharmaceutical company Vifor Pharma Ltd.</p><p>Industry News</p><p>Funds</p><p>Health Velocity Capital, a San Francisco- and Nashville, Tenn.-based venture firm, has raised more than $300 million for its latest fund. The firm will invest in early- and growth-stage companies. The fund's limited partners include institutional investors, health insurers, health systems and health-technology companies.</p><p>People</p><p>San Francisco-based Artis Ventures has promoted Ameena El-Bibany to partner. She joined Artis in 2019 and has led the firm's investment in digital-surgery company Activ Surgical, where she serves on the board. She invests in drug discovery, high-throughput synthetic-biology systems, computational biology, personalized medicine and other sectors. Before working in venture capital, she worked at industrial-enzyme company Novozymes.</p><p>New Money</p><p>Found Health Inc., a San Francisco-based health technology weight-management service, raised $100 million in Series B funding led by WestCap Group with participation from Institutional Venture Partners, the Chernin Group, G9 Ventures, and Able Partners, GV and Atomic Labs.</p><p>Pair Eyewear, a New York-based direct-to-consumer, customizable-eyewear brand, closed a $60 million Series B round. New Enterprise Associates and Connect Ventures led the investment, which included contributions from Javelin Ventures, Norwest Venture Partners and others.</p><p>Garner Health, a New York-based startup whose technology helps employees find the best doctor for their needs, landed $45 million in Series B funding. Redpoint Ventures led the round, which included support from Founders Fund, Thrive Capital and Optum Ventures.</p><p>Belong Health, a company partnering with local and regional health plans and hospital systems to support the delivery of Medicare Advantage and special-needs plan products, has raised $40 million in Series A funding led by New Enterprise Associates with continued participation from seed investor Maverick Ventures. Mohamad Makhzoumi, managing general partner, healthcare at NEA, will join Belong Health's board.</p><p>Parallel Learning, a digital-health startup providing services to families, educators and students dealing with learning and thinking differences, launched with $2.8 million in funding. Eric Reiner and Dan Povitsky of Vine Ventures led the round, which included support from Global Founders Capital, Great Oaks Venture Capital and others.</p><p>More Health News</p><p>U.S. healthcare spending rose nearly 10% in 2020, report finds</p><p>In a bad year for biotech stocks, deals and vaccines were winners</p><p>Three miles and $400 apart: hospital prices vary wildly even in the same city</p><p>CDC's early Covid-19 test hampered by design flaw, contamination</p><p>Around the Web</p><p>Lilly to begin 2022 with FDA filing for Alzheimer's drug candidate (Fierce Biotech)</p><p>Will we always need Covid-19 boosters? Experts have theories (STAT News)</p><p>Universal coronavirus vaccinesâ€”an urgent need (New England Journal of Medicine)</p><p>As Omicron outbreak increases, colleges are recalculating pandemic risks (Boston Globe)</p>",
  "published": "2021-12-16T14:41:00.000Z",
  "tags": [
    {
      "id": "US46625H1005",
      "nexusId": "10009914",
      "name": "JPMorgan Chase & Co.",
      "offsets": [
        {
          "start": 91,
          "end": 99
        },
        {
          "start": 116,
          "end": 127
        }
      ]
    }
  ]
}